MedPath

Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)

Completed
Conditions
Respiratory Distress Syndrome, Newborn
Registration Number
NCT01102543
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Brief Summary

The aim of Alizé is to describe a population of premature babies (gestational age (GA) \< 32 weeks) in real life situation and the management of RDS.

Detailed Description

Description includes gestational age, birth clinical characteristics in particular the respiratory function, evaluation of the mother prenatal corticosteroids treatment in prophylaxis of RDS, mother medical and obstetric history, premature babies care in the delivery room with a special focus on the Curosurf use: prophylactic or curative use / other surfactant / no surfactant. A special focus is on the Prophylactic use.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
972
Inclusion Criteria
  • during the study, each neonatologist will have to include all the babies born with a gestational age < 32 GA
Exclusion Criteria
  • gestational age > 32 GA
  • No consent to the data collection by one of the parents

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Laboratoire Chiesi S.A.

🇫🇷

Courbevoie, France

© Copyright 2025. All Rights Reserved by MedPath